[go: up one dir, main page]

FR24C1022I2 - Modulation d'activité du complément - Google Patents

Modulation d'activité du complément

Info

Publication number
FR24C1022I2
FR24C1022I2 FR24C1022C FR24C1022C FR24C1022I2 FR 24C1022 I2 FR24C1022 I2 FR 24C1022I2 FR 24C1022 C FR24C1022 C FR 24C1022C FR 24C1022 C FR24C1022 C FR 24C1022C FR 24C1022 I2 FR24C1022 I2 FR 24C1022I2
Authority
FR
France
Prior art keywords
modulation
complement activity
complement
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1022C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Inc
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1022(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of FR24C1022I1 publication Critical patent/FR24C1022I1/fr
Application granted granted Critical
Publication of FR24C1022I2 publication Critical patent/FR24C1022I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR24C1022C 2014-06-12 2024-05-16 Modulation d'activité du complément Active FR24C1022I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US201562108772P 2015-01-28 2015-01-28
PCT/US2015/035473 WO2015191951A2 (fr) 2014-06-12 2015-06-12 Modulation d'activité du complément

Publications (2)

Publication Number Publication Date
FR24C1022I1 FR24C1022I1 (fr) 2024-07-19
FR24C1022I2 true FR24C1022I2 (fr) 2025-05-23

Family

ID=54834568

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1022C Active FR24C1022I2 (fr) 2014-06-12 2024-05-16 Modulation d'activité du complément

Country Status (31)

Country Link
US (7) US10106579B2 (fr)
EP (4) EP3154561B1 (fr)
JP (4) JP6432954B2 (fr)
KR (3) KR101981532B1 (fr)
CN (3) CN119236050A (fr)
AP (1) AP2016009612A0 (fr)
AU (3) AU2015274482B2 (fr)
BR (3) BR122021025449B1 (fr)
CA (3) CA3241273A1 (fr)
CY (3) CY1122227T1 (fr)
DK (2) DK3154561T3 (fr)
ES (2) ES2750556T3 (fr)
FI (1) FIC20240015I1 (fr)
FR (1) FR24C1022I2 (fr)
HR (2) HRP20211561T8 (fr)
HU (3) HUE045646T2 (fr)
IL (3) IL249093B (fr)
LT (3) LT3628680T (fr)
MX (2) MX2016016449A (fr)
NL (1) NL301275I2 (fr)
NO (1) NO2024023I1 (fr)
NZ (1) NZ727420A (fr)
PL (2) PL3628680T3 (fr)
PT (2) PT3154561T (fr)
RS (2) RS59353B1 (fr)
RU (1) RU2670988C2 (fr)
SG (1) SG11201610222UA (fr)
SI (2) SI3628680T1 (fr)
SM (2) SMT202100588T1 (fr)
WO (1) WO2015191951A2 (fr)
ZA (3) ZA201706379B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101981532B1 (ko) 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
RU2733720C2 (ru) * 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
US11026945B2 (en) 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US11814445B2 (en) * 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
ES3013570T3 (en) 2018-06-21 2025-04-14 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
SG11202103972SA (en) * 2018-10-22 2021-05-28 Ra Pharmaceuticals Inc Neurological disease treatment with zilucoplan
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
US20220211799A1 (en) * 2019-04-24 2022-07-07 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
ES2973767T3 (es) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento
ES3013485T3 (en) 2019-09-12 2025-04-14 Ra Pharmaceuticals Inc Treatment of a neurological disease with complement inhibitors
MX2022006514A (es) 2019-12-26 2022-07-11 Eisai R&D Man Co Ltd Composicion farmaceutica que contiene un acido ribonucleico de doble hebra que inhibe la expresion de c5 de complemento.
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
CA3204051A1 (fr) 2021-01-20 2022-07-28 Brian Lian Compositions et procedes pour le traitement de troubles metaboliques et hepatiques
WO2022177635A2 (fr) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions et méthodes pour le traitement de maladies microbiennes
WO2023044290A1 (fr) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions et méthodes de traitement de troubles métaboliques et hépatiques
WO2023215294A1 (fr) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la voie du complément à des fins de cicatrisation
WO2024039636A1 (fr) * 2022-08-16 2024-02-22 Ps Therapy, Inc. Procédés d'utilisation de disulfirame et de métabolites de celui-ci
TW202506645A (zh) * 2023-03-31 2025-02-16 美商弗列克斯美國公司 雜芳基抗降解劑

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2641081A1 (fr) * 1988-12-23 1990-06-29 Medgenix Group
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2067194C (fr) 1989-10-05 2003-03-18 Glenn Kawasaki Synthese sans cellules et isolement de nouveaux genes et polypeptides
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
JPH08510325A (ja) 1993-05-28 1996-10-29 カイロン コーポレイション 生物学的に活性なペプチド配列の選択方法
EP0710243B1 (fr) 1993-06-29 2000-06-14 Ferring B.V. Synthese de peptides cycliques
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
DE69739163D1 (de) 1996-10-17 2009-01-22 Mitsubishi Chem Corp Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP0985039B1 (fr) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Polypeptides d'anticorps artificiels
EP0896001A1 (fr) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Procédé pour la préparation de dérivés d'antagonistes de l'oxytocin, produits intérmédiares pour la préparation de dérivés d'antagonistes de l'oxytocin et procédé pour la préparation de produits intermédiares
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
WO2000007979A2 (fr) 1998-08-07 2000-02-17 Emisphere Technologies, Inc. Composes et compositions pour l'administration de principes actifs
EP1115847A1 (fr) * 1998-09-25 2001-07-18 Children's Medical Center Corporation Peptides courts modulant selectivement l'activite des proteines kinases
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
WO2003074992A2 (fr) * 2002-03-01 2003-09-12 Mds Proteomics Inc. Proteines phosphorylees et utilisations associees
US7411039B2 (en) * 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
EP2292259A3 (fr) * 2002-11-15 2011-03-23 MUSC Foundation For Research Development Modulateurs de complément cibles sur le récepteur 2 de complément
NZ572274A (en) * 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
JP4768620B2 (ja) 2003-05-15 2011-09-07 ジェネンテック， インコーポレイテッド 敗血症の予防及び治療のための方法及び組成物
WO2005023866A2 (fr) * 2003-09-10 2005-03-17 Baxter International Inc. Peptides permettant d'inhiber l'activation du complement
CA2537029C (fr) 2003-11-26 2013-03-12 Likan Liang Systemes micellaires convenant pour l'apport de composes lipophiles ou hydrophobes
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
WO2006066258A2 (fr) * 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugaison de peptides
SI1844337T1 (sl) 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
WO2006105214A2 (fr) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction de l'activation du complement et de l'inflammation dans une lesion tissulaire a l'aide de carotenoides, d'analogues de carotenoides ou de derives de carotenoides
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
ES2399645T3 (es) 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
EP1876183A1 (fr) * 2006-07-04 2008-01-09 Technische Universität München Peptides d'une longueur minimalisée ayant une haute affinité pour protéines de facteur VIII et des protéines analogue à facteur VIII
EP3028716B1 (fr) 2006-10-10 2020-09-16 Regenesance B.V. Inhibition du complément pour régénération nerveuse améliorée
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
WO2008109742A1 (fr) 2007-03-06 2008-09-12 Novo Nordisk A/S Modulation d'activation de système du complément pour traitement d'inflammation liée à un saignement
EP2129681A2 (fr) * 2007-03-22 2009-12-09 Novartis Ag Antigènes c5 et leurs utilisations
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
WO2008137236A2 (fr) 2007-04-30 2008-11-13 Alcon Research, Ltd. Traitement de la dégénérescence maculaire liée à l'âge en utilisant des inhibiteurs du facteur d du complément
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US20110142837A1 (en) 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
MX2010003630A (es) 2007-10-02 2010-04-21 Potentia Pharmaceuticals Inc Administracion sostenida de analogos de compstatina desde geles.
WO2009067191A2 (fr) 2007-11-16 2009-05-28 The General Hospital Corporation Procédés et compositions pour le traitement d'une infection par le virus de l'hépatite c (vhc)
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20100093624A1 (en) 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
WO2010015608A1 (fr) * 2008-08-05 2010-02-11 Novartis Ag Compositions et procédés pour des anticorps ciblant une protéine du complément c5
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
RS64039B1 (sr) 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
WO2011106635A1 (fr) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Traitement de la sepsie utilisant des inhibiteurs du complément
WO2011112999A2 (fr) 2010-03-12 2011-09-15 The Regents Of The University Of California Conjugués lipide-peptide-polymère et leurs nanoparticules
WO2011139343A2 (fr) * 2010-04-28 2011-11-10 Wu Nian Conjugués peg-lipide reliés à un acide aminé
EP2563359A1 (fr) 2010-04-30 2013-03-06 Allergan, Inc. Nouveau traitement pour la dégénérescence maculaire liée à l'âge et la maladie ischémique oculaire associée à l'activation du complément par le ciblage de la 5-lipoxygénase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
SG10201601789TA (en) * 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
KR20220044616A (ko) 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
WO2012162215A1 (fr) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion de la cicatrisation de fracture à l'aide d'inhibiteurs du complément
WO2012174055A1 (fr) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Cicatrisation d'une plaie à l'aide d'inhibiteurs du complément
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
WO2013052736A2 (fr) * 2011-10-06 2013-04-11 The Medicines Company Procédés de traitement ou de prévention de la perte de sang pendant une chirurgie à l'aide de l'inhibiteur de la sérine protéase mdco-2010
WO2013126006A1 (fr) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides se fixant au composant c5 du complément humain
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
ES2755104T3 (es) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (fr) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition pour la néphropathie lupique et ses méthodes de fabrication et d'utilisation
US20150330989A1 (en) 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) * 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
EP3119802B1 (fr) 2014-03-20 2019-12-04 InflaRx GmbH Inhibiteurs de c5a pour le traitement de la pneumonie virale
KR101981532B1 (ko) 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
WO2016094834A2 (fr) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Méthode de traitement d'une affection à médiation par le complément provoquée par un agent infectieux chez un patient
CN107427482A (zh) 2015-01-21 2017-12-01 帕西拉制药有限公司 凝血酸的多囊脂质体制剂
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
WO2017035362A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Utilisation de composés inhibiteurs de la voie du complément pour atténuer des réponses immunitaires indésirables associées à une thérapie adoptive par lymphocytes t
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
WO2019051436A1 (fr) 2017-09-11 2019-03-14 Ra Pharmaceuticals, Inc. Formulations pour l'administration de composés
TW201938184A (zh) 2017-12-04 2019-10-01 美商Ｒａ製藥公司 補體活性之調節劑
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
US20220211799A1 (en) 2019-04-24 2022-07-07 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Also Published As

Publication number Publication date
BR122023024819A2 (pt) 2023-12-26
AU2021204313B2 (en) 2024-01-04
EP3628680B1 (fr) 2021-09-08
LT3628680T (lt) 2021-11-25
ZA201706379B (en) 2018-12-19
IL249093B (en) 2020-05-31
CN106456701A (zh) 2017-02-22
IL281264B (en) 2022-05-01
FR24C1022I1 (fr) 2024-07-19
AU2015274482A1 (en) 2017-01-12
US10106579B2 (en) 2018-10-23
LTPA2024514I1 (fr) 2024-06-10
IL273746A (en) 2020-05-31
KR101981532B1 (ko) 2019-09-02
CA2949985A1 (fr) 2015-12-17
SI3628680T1 (sl) 2021-12-31
CN111187338B (zh) 2024-08-02
RS62428B1 (sr) 2021-11-30
US11014965B2 (en) 2021-05-25
KR20170003993A (ko) 2017-01-10
HUS2400015I1 (hu) 2024-06-28
DK3154561T3 (da) 2019-10-07
JP6770043B2 (ja) 2020-10-14
US20180371019A1 (en) 2018-12-27
NZ727420A (en) 2018-06-29
US20200123202A1 (en) 2020-04-23
US20170137468A1 (en) 2017-05-18
US10562934B2 (en) 2020-02-18
AU2015274482B2 (en) 2018-11-08
NL301275I2 (nl) 2024-06-20
US20190119328A1 (en) 2019-04-25
IL281264A (en) 2021-04-29
KR102503319B1 (ko) 2023-02-28
JP2019048834A (ja) 2019-03-28
US11965040B2 (en) 2024-04-23
AU2021204313A1 (en) 2021-07-22
HRP20211561T8 (hr) 2022-03-04
CY1124595T1 (el) 2022-07-22
IL273746B (en) 2021-03-25
HUE045646T2 (hu) 2020-01-28
KR20220002727A (ko) 2022-01-06
CY2024015I1 (el) 2024-12-13
SI3154561T1 (sl) 2019-11-29
JP6432954B2 (ja) 2018-12-05
ZA202001859B (en) 2021-04-28
CN106456701B (zh) 2020-01-07
KR102346228B1 (ko) 2022-01-04
JP2020128417A (ja) 2020-08-27
DK3628680T3 (da) 2021-10-11
US10435438B2 (en) 2019-10-08
RU2018136750A (ru) 2018-11-06
JP7002597B2 (ja) 2022-02-04
NZ736573A (en) 2024-03-22
MX2021009309A (es) 2021-10-26
FIC20240015I1 (fi) 2024-05-28
HUE055931T2 (hu) 2022-01-28
HRP20191763T1 (hr) 2019-12-27
CA3174909A1 (fr) 2015-12-17
WO2015191951A3 (fr) 2016-03-03
BR112016029076A2 (pt) 2018-06-05
NZ761610A (en) 2024-03-22
BR122021025449B1 (pt) 2024-02-15
CY1122227T1 (el) 2020-11-25
CA3241273A1 (fr) 2015-12-17
EP3154561A4 (fr) 2018-04-18
EP3628680A1 (fr) 2020-04-01
ES2895029T3 (es) 2022-02-17
IL249093A0 (en) 2017-01-31
CN111187338A (zh) 2020-05-22
RS59353B1 (sr) 2019-10-31
RU2670988C2 (ru) 2018-10-29
ZA201900497B (en) 2019-10-30
CN119236050A (zh) 2025-01-03
MX2016016449A (es) 2017-08-24
PL3154561T3 (pl) 2019-12-31
HRP20211561T1 (hr) 2021-12-24
ES2750556T3 (es) 2020-03-26
PT3628680T (pt) 2021-10-07
JP2017523232A (ja) 2017-08-17
US20200002380A1 (en) 2020-01-02
JP2022034057A (ja) 2022-03-02
BR112016029076B1 (pt) 2024-02-15
EP3973994A1 (fr) 2022-03-30
PT3154561T (pt) 2019-10-25
CY2024015I2 (el) 2024-12-13
EP3154561A2 (fr) 2017-04-19
LTC3154561I2 (fr) 2025-11-10
PL3628680T3 (pl) 2022-01-10
LT3154561T (lt) 2019-11-25
CA2949985C (fr) 2023-10-17
EP4223317A2 (fr) 2023-08-09
WO2015191951A2 (fr) 2015-12-17
JP7454545B2 (ja) 2024-03-22
SMT201900568T1 (it) 2019-11-13
RU2016147080A3 (fr) 2018-06-01
BR112016029076A8 (pt) 2022-02-08
KR20190057420A (ko) 2019-05-28
US20210246167A1 (en) 2021-08-12
RU2016147080A (ru) 2018-06-01
EP3154561B1 (fr) 2019-09-04
NO2024023I1 (no) 2024-05-24
US10208089B2 (en) 2019-02-19
AU2019200828B2 (en) 2021-04-08
EP4223317A3 (fr) 2023-09-27
US11535650B1 (en) 2022-12-27
AU2019200828A1 (en) 2019-02-28
AP2016009612A0 (en) 2016-12-31
SMT202100588T1 (it) 2021-11-12
RU2018136750A3 (fr) 2021-10-19
SG11201610222UA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
FR24C1022I2 (fr) Modulation d'activité du complément
IL273404A (en) Compositions for modulating sod-1 expression
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
LT3206715T (lt) Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui
EP4015648C0 (fr) Réduction de la rétention d'introns
PL3387907T3 (pl) Zastosowanie 3-izoksazolidonów jako selektywnych herbicydów
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3107563T3 (da) Glycomålrettede terapeutiske midler
DK3231444T3 (da) Ny behandling
EP3250230A4 (fr) Modulateurs d'activité du complément
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
LT3685847T (lt) Komplemento aktyvumo moduliatoriai
DK3113761T3 (da) Mikrokapsler indeholdende aktivt middel
DK3132009T3 (da) Fremgangsmåde
HUE043624T2 (hu) Trifluormetil-alkoholok ROR-gamma-t modulátoraiként
HUE056544T2 (hu) Gamma-C-citokin aktivitás modulálása
DK3160252T3 (da) Ny fedtfri konfekture
DK3143123T3 (da) Mikrorna-induktion af kardiologisk regenerering
PL3145592T3 (pl) Kompozycja do pielęgnacji skóry
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
IL252191B (en) Compositions and methods for modulating at2r activity
EP3384786A4 (fr) Utilisation d'isoquercitrine modifiée par enzyme
TH1401001808B (th) เครื่องขัดผิว
TH1401001806B (th) เครื่องขัดผิว
TH1601001543A (th) สารรวมของสารประกอบออกฤทธิ์